Pasithea Therapeutics Corp. held its Annual Meeting on September 9, 2026, where shareholders approved the election of Dr. Tiago Reis Marques and Prof. Lawrence Steinman as Class III directors and ratified CBIZ CPAs P.C. as the independent auditor for fiscal year 2026. Crucially, stockholders authorized an amendment to the Certificate of Incorporation granting the Board discretion to effect a reverse stock split at any time within one year, with a ratio ranging from 1-for-2 to 1-for-20; the exact ratio and effective date remain undetermined by the Board. Pasithea Therapeutics Corp. operates in the biotechnology industry, focusing on drug discovery and development.